Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 525

1.

Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease.

Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH, Hammill BG, Pun PH, Curtis JP, Anstrom KJ, Hammill SC, Al-Khatib SM.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):793-9. doi: 10.1161/CIRCEP.114.001455. Epub 2014 Jul 18.

2.

Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.

Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV Jr, Navaneethan SD.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1119-27. doi: 10.2215/CJN.11121114. Epub 2015 Jun 25.

3.

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Khazanie P, Hellkamp AS, Fonarow GC, Bhatt DL, Masoudi FA, Anstrom KJ, Heidenreich PA, Yancy CW, Curtis LH, Hernandez AF, Peterson ED, Al-Khatib SM.

J Am Heart Assoc. 2015 Aug 6;4(8):e002061. doi: 10.1161/JAHA.115.002061.

4.

Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.

Khazanie P, Greiner MA, Al-Khatib SM, Piccini JP, Turakhia MP, Varosy PD, Masoudi FA, Curtis LH, Hernandez AF; National Cardiovascular Data Registry.

Circ Heart Fail. 2016 Jun;9(6). pii: e002324. doi: 10.1161/CIRCHEARTFAILURE.115.002324.

5.

Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.

Madhavan M, Waks JW, Friedman PA, Kramer DB, Buxton AE, Noseworthy PA, Mehta RA, Hodge DO, Higgins AY, Webster TL, Witt CM, Cha YM, Gersh BJ.

Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003283. doi: 10.1161/CIRCEP.115.003283.

6.

Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.

Bansal N, Szpiro A, Masoudi F, Greenlee RT, Smith DH, Magid DJ, Gurwitz JH, Reynolds K, Tabada GH, Sung SH, Dighe A, Cassidy-Bushrow A, Garcia-Montilla R, Hammill S, Hayes J, Kadish A, Sharma P, Varosy P, Vidaillet H, Go AS.

Heart. 2017 Apr;103(7):529-537. doi: 10.1136/heartjnl-2016-309842. Epub 2016 Oct 14.

7.

Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306. Epub 2015 Feb 10.

8.

Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.

Fröhlich GM, Holzmeister J, Hübler M, Hübler S, Wolfrum M, Enseleit F, Seifert B, Hürlimann D, Lehmkuhl HB, Noll G, Steffel J, Falk V, Lüscher TF, Hetzer R, Ruschitzka F.

Heart. 2013 Aug;99(16):1158-65. doi: 10.1136/heartjnl-2013-304185. Epub 2013 Jun 27.

PMID:
23813845
9.

Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.

Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, Sanders GD, Yancy CW, Al-Khatib SM.

Circ Heart Fail. 2016 Jan;9(1):e002630. doi: 10.1161/CIRCHEARTFAILURE.115.002630.

10.

Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.

Amit G, Suleiman M, Konstantino Y, Luria D, Kazatsker M, Chetboun I, Haim M, Gavrielov-Yusim N, Goldenberg I, Glikson M; Israeli Working Group on Pacing and Electrophysiology.

Europace. 2014 Aug;16(8):1175-80. doi: 10.1093/europace/euu015. Epub 2014 Feb 19.

PMID:
24554524
11.

Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.

Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Køber L, Thune JJ.

Circulation. 2017 Nov 7;136(19):1772-1780. doi: 10.1161/CIRCULATIONAHA.117.028829. Epub 2017 Sep 6.

PMID:
28877914
12.

Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.

Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E, Rangel-Sousa D, Esteve-Ruiz IM, Martínez-Martínez A.

Transplant Proc. 2013;45(10):3659-61. doi: 10.1016/j.transproceed.2013.10.017.

PMID:
24314988
13.

Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.

Providência R, Marijon E, Lambiase PD, Bouzeman A, Defaye P, Klug D, Amet D, Perier MC, Gras D, Algalarrondo V, Deharo JC, Leclercq C, Fauchier L, Babuty D, Bordachar P, Sadoul N, Piot O, Boveda S.

J Am Heart Assoc. 2016 Feb 12;5(2). pii: e002756. doi: 10.1161/JAHA.115.002756.

14.

Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).

Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Eldadah Z, Ellenbogen KA, Dickfeld T, Spragg DD, Marine JE, Guallar E, Tomaselli GF.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1084-91. doi: 10.1161/CIRCEP.113.001705. Epub 2014 Oct 1.

15.

Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients.

Pokorney SD, Hellkamp AS, Yancy CW, Curtis LH, Hammill SC, Peterson ED, Masoudi FA, Bhatt DL, Al-Khalidi HR, Heidenreich PA, Anstrom KJ, Fonarow GC, Al-Khatib SM.

Circ Arrhythm Electrophysiol. 2015 Feb;8(1):145-51. doi: 10.1161/CIRCEP.114.001878. Epub 2014 Dec 12.

16.

Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.

Martens P, Verbrugge FH, Nijst P, Dupont M, Nuyens D, Herendael HV, Rivero-Ayerza M, Tang WH, Mullens W.

Heart. 2017 Dec;103(24):1977-1984. doi: 10.1136/heartjnl-2017-311423. Epub 2017 Jul 17.

PMID:
28716973
17.

Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease.

Friedman DJ, Singh JP, Curtis JP, Tang WHW, Bao H, Spatz ES, Hernandez AF, Patel UD, Al-Khatib SM.

J Am Coll Cardiol. 2015 Dec 15;66(23):2618-2629. doi: 10.1016/j.jacc.2015.09.097.

18.

Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.

Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):706-13. doi: 10.1161/CIRCEP.112.970798. Epub 2012 Jun 8.

19.

Clinical Outcomes of Single- versus Dual-Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry.

Konstantino Y, Haim M, Boxer J, Goldenberg I, Feldman A, Michowitz Y, Glikson M, Suleiman M; Israeli Working Group on Pacing and Electrophysiology.

J Cardiovasc Electrophysiol. 2016 Jun;27(6):718-23. doi: 10.1111/jce.12953. Epub 2016 Mar 18.

PMID:
26852908
20.

Clinical Outcomes in Patients with Severe Renal Dysfunction Including Dialysis Following Defibrillator Implantation.

Bogdan S, Nof E, Eisen A, Sela R, Rosenheck S, Freedberg N, Geist M, Ben-Zvi S, Haim M, Glikson M, Goldenberg I, Suleiman M; Israeli working group of pacing and electrophysiology of the Israeli Heart Society.

Am J Nephrol. 2015;42(4):295-304. doi: 10.1159/000440772. Epub 2015 Oct 31.

PMID:
26529418

Supplemental Content

Support Center